MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia. - Kagawa, Yosuke; Nosaki, Kaname; Matsumoto, Shingo; Kato, Terufumi; Nakamura, Atushi; Shingyoji, Masato; Nishino, Kazumi; Tabata, Eriko; Furuya, Naoki; Miyamoto, Shingo; Sakakibara, Jun; Nakao, Mika; et al. (Annals of Oncology, 2022)